Granowska M, Britton K E, Mather S J, Lowe D G, Ellison D, Bomanji J, Burchell J, Taylor-Papadimitriou J, Hudson C R, Shepherd J H
Nuclear Medicine Department, St. Bartholomew's Hospital, West Smithfield, London, UK.
Eur J Nucl Med. 1993 Jun;20(6):483-9. doi: 10.1007/BF00175160.
Radioimmunoscintigraphy (RIS) with technetium-99m labelled SM3, a monoclonal antibody reacting with a polymorphic epithelial mucin glycoprotein core antigen, is evaluated. No adverse effects or thyroid uptake were observed. Studies in 45 patients (one twice) had a sensitivity for gynaecological malignancy of 100% (35/35) and a specificity of 73% (8/11), giving an overall accuracy of 93% (43/46). These results have led to the routine adoption of 99mTc RIS in the management of patients suspected of or having primary or recurrent gynaecological cancer.
对用99m锝标记的SM3进行放射免疫闪烁显像（RIS）进行了评估，SM3是一种与多态性上皮粘蛋白糖蛋白核心抗原发生反应的单克隆抗体。未观察到不良反应或甲状腺摄取情况。对45例患者（其中1例进行了两次检查）的研究显示，对妇科恶性肿瘤的敏感性为100%（35/35），特异性为73%（8/11），总体准确率为93%（43/46）。这些结果使得99m锝RIS在疑似患有或患有原发性或复发性妇科癌症的患者管理中得到常规应用。
